Y-mAbs(YMAB) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments Princeton, NJ, August 8, 2025 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025. Recent Transaction Announ ...